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We retrospectively reviewed 27 cases diagnosed as idiopathic optic neuritis between 1992
and 2001 at Kaohsiung Veterans General Hospital to assess the clinical features, visual
prognosis, neuroimaging, laboratory studies, and development of multiple sclerosis in
Chinese patients with optic neuritis. Patient age ranged from 13 to 54 years (mean, 35.8 ±
11.3 years). Five cases presented as bilateral optic neuritis and 22 as unilateral. Visual function
improved gradually from 2 weeks after treatment. Twelve (44.4%) cases showed disc swelling
and ocular pain was also noted in 44.4% of patients. All cases that underwent visual field
and visual evoked potential tests showed abnormality in lesion eyes. Of the 23 cases that
underwent neuroimaging studies, including computerized tomography (17 patients) and
magnetic resonance imaging (6 patients), 10 revealed optic nerve thickening. Four cases
(14.8%) developed multiple sclerosis during follow-up (mean, 4.3 years). The incidence of
disc swelling was higher than that reported by the Optic Neuritis Treatment Trial, but the
incidence of initial ocular pain, the presence of periventricular plaques, and the development
of multiple sclerosis were lower in our study. The unilateral group had significantly better
visual outcome than the bilateral group.
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Optic neuritis (ON) is an inflammatory demyelinating
disorder of the optic nerve. Most cases are idiopathic
or associated with multiple sclerosis (MS) [1]. ON is
characterized by acute or subacute visual loss, often
associated with retrobulbar pain or pain with eye
movement. It usually affects patients 15–45 years of
age, predominantly women. Generally, the condition
is unilateral and accompanied by decreased color
vision and a central or cecocentral scotoma in the
affected eye. The optic disc may appear normal or
edematous (papill it is) .  The clinical course is
characterized by steadily worsening vision, which
reaches its nadir by about 1 week. Most patients recover
vision gradually over several months. The diagnosis
of ON rests principally on the patient’s history and
cl inical  f indings,  despite  the avai labi l i ty of
neuroimaging and laboratory studies. Evaluation
should include a complete eye examination and visual
function testing of both eyes. The history should include
recent viral illness, family history of vision loss or MS,
and past episodes of ON [1,2]. ON may cause thickening
of the nerve on imaging studies; fat-suppressed
gadolinium-enhanced magnetic resonance imaging
(MRI) gives the best result. The value of corticosteroid
treatment for this condition was investigated in the
Optic Neuritis Treatment Trial (ONTT) [3].
The prevalence of ON in Chinese people is not as
high as in Western countries [4,5]. The clinical picture,
prognosis, and linkage to MS may also be different in
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Chinese people and Caucasians. We compared the
difference between ON patients in our series and the
ONTT results. We also wondered if there might be
differences between unilateral and bilateral ON.
PATIENTS AND METHODS
We retrospectively reviewed cases diagnosed as idio-
pathic ON at Kaohsiung Veterans General Hospital
from August 1992 to October 2001. Eligibility criteria
for enrolment included: age between 13 and 54 years,
an acute clinical syndrome consistent with unilateral
or bilateral ON, visual symptoms of 14 days’ duration
or less, a relative afferent pupillary defect in the uni-
laterally affected eye, and a visual field defect in the
affected eye. An acute symptom was characterized by
acute or subacute vision loss. Optic nerve swelling
could be visible on fundus examination. Table 1 shows
the major exclusion criteria.
For each patient enrolled in the study, a detailed
history about visual symptoms, presence of initial
ocular pain, and past history of ocular, neurologic,
and systemic problems was elicited. No evidence of
uveitis, glaucoma, retinopathy, sarcoidosis, syphilis,
immune deficiency disease, neoplasia, or connective
tissue diseases were noted in any patients, and stand-
ardized ocular and visual function examinations were
performed, as described below.
Patients underwent visual examination at the first
visit and 2 weeks, 1 month (± 5 days), 3 months (± 2
weeks), 6 months (± 1 month), and 1 year (± 1 month)
later, and at the last follow-up. We performed several
visual function measurements including best corrected
visual acuity (BCVA), color vision, and visual field.
The visual acuity was measured using a Snellen chart
at 6 m and visual acuity data were transformed to
logMAR scores for analysis [6]. Color vision was tested
using pseudoisochromatic Ishihara plates (total 21
plates), giving a score of 0 to 21 with 21 considered
normal color vision [7]. The visual field was evaluated
using the Octopus automated perimetry G1 program.
Goldmann perimetry or frequency doubling techno-
logy was used when patients could not undergo Octo-
pus perimetry testing. The methods for visual field
classification were the same as those used in ONTT [8].
For each patient, the visual field was judged to be
either normal or abnormal; abnormal visual fields
were divided into eight categories (diffuse depression,
central scotoma, cecocentral scotoma, altitudinal visual
field defect, arcuate scotoma, blind spot enlargement,
nasal island, and temporal island).
Each patient underwent a standardized neurologic
examination, a complete ocular examination, includ-
ing anterior segment and fundi, standardized brain
radioimaging including MRI or computerized tomo-
graphy (CT), visual evoked potential (VEP) tests, and
blood examinations for anti-nuclear antibody (ANA),
syphilis (Venereal Disease Research Laboratory,
VDRL), CBC (complete blood count), and erythrocyte
sedimentation rate (ESR). The history included recent
viral illness, family history of vision loss or MS, past
episodes of ON, and systemic disease such as diabetes
mellitus and hypertension. If ON occurred in both
eyes within 1 week, we assumed the case to be bilateral.
In order to reveal the difference in outcomes between
unilateral and bilateral cases, patients were divided
into two groups for comparison. The differences in
BCVA and color vision in unilateral and bilateral
groups were analyzed using the independent t-test.
Table 1. Major exclusion criteria
Evidence of optic disc pallor in affected eyes
Treatment for optic neuritis already instituted
Corticosteroids already administered for systemic disease
Preexisting ocular abnormalities that might affect assessment of visual function
Ischemic optic neuropathy
Traumatic or compressive optic neuropathy
Systemic disease as a predisposing factor for ischemic optic neuropathy (e.g. uncontrolled hypertension, heart disease
such as pathologic arrhythmia)
Systemic lupus erythematosus, leukemia
Patient receiving medication that may produce retinal or optic nerve toxicity (e.g. ethambutol, phenothiazine)
Toxic material exposure at work or possible alcoholism
Brain tumor
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The prognosis of visual acuity and color vision in each
group was analyzed by the paired t-test.
If idiopathic ON was suspected, intravenous meth-
ylprednisolone 250 mg four times a day was given for
3 to 5 days, followed by oral prednisolone (1 mg/kg/
day), which was tapered gradually within about 1.5
months according to clinical features and patients’
ability to tolerate the treatment. In addition to steroid
treatment, some patients were given oral vitamin B-
complex.
RESULTS
A total of 27 patients were included in the study (Table
2); 18 were females (66.7%). The mean age was 35.8 ±
11.3 years. Among 22 unilateral cases, 13 involved the
left eye and nine the right eye. Five cases were bilateral.
During the follow-up period, five cases had disease
recurrence, of whom four had unilateral attacks and
one had a bilateral attack. The mean follow-up period
was 4.3 ± 1.7 years, ranging from 14 months to 9 years.
Initial ocular or periocular pain was noted in 44.4%
of patients and disc swelling was seen in 12 (44.4%)
patients. One case (3.7%) had definite MS at the first
visit. During the follow-up, four more patients devel-
oped MS.
In the unilateral group, visual function including
both BCVA and color test started to improve 2 weeks
after treatment (Tables 3 and 4, Figure). BCVA in the
unilateral group was better than that in the bilateral
group, at both the initial stage and 1 year later. Recov-
ery of color vision was better in the unilateral group
than in the bilateral group. Thirteen patients (63.6%)
in the unilateral group gained useful vision (> 0.5) by
the last visit, but none of the bilateral group showed
final visual acuity better than 0.5. Nineteen patients
(86.4%) in the unilateral group gained vision better
than 20/200, but only one case (20%) in the bilateral
group gained vision better than 20/200 by the last
visit.
All 23 patients who underwent a visual field test
had abnormality in the clinically affected eyes (Table
5). Visual field defects included general depression or
Table 2. Clinical characteristics of patients
Unilateral Bilateral p value
Number of patients 22 5
Female 14 (63.7%) 4 (80%)
Age (mean) 36.3 33.8
Periocular pain 10 (45.5%) 2 (40%)
Disc swelling 10 2
VA* (mean at first visit) 1.03 ± 0.68 1.60 ± 0.14 0.001
Color vision† (mean at first visit) 4.45 ± 6.93 0.2 ± 0.45 < 0.001
*LogMAR conversions for Snellen visual acuity scores: < 5/200: 1.7, 5/200: 1.6, 5/125: 1.4, 10/200: 1.3, 10/160: 1.2, 10/125: 1.1, 20/200: 1.0,
20/160: 0.9, 20/125: 0.8, 20/100: 0.7, 20/80: 0.6, 20/63: 0.5, 20/50: 0.4, 20/40: 0.3, 20/25: 0.1, 20/20: 0, 20/16: –0.1, 20/13: –0.2. †Ishihara
pseudoisochromatic plates score, 0–21.
Table 3. Improvement in visual acuity (VA; logMAR) compared with initial visit
Unilateral p* Bilateral p** p***
2 weeks after treatment 0.50 ± 0.65 0.003 1.57 ± 0.19 0.788 < 0.001
1 month after treatment 0.38 ± 0.58 < 0.001 1.37 ± 0.27 0.481 0.002
3 months after treatment 0.37 ± 0.49 < 0.001 1.31 ± 0.74 0.461 0.002
6 months after treatment 0.42 ± 0.54 < 0.001 1.31 ± 0.74 0.461 0.005
1 year after treatment 0.39 ± 0.47 < 0.001 1.28 ± 0.69 0.439 0.005
*Comparison with initial VA (paired t-test) in unilateral group; **comparison with initial VA (paired t-test) in bilateral group; ***comparison
of unilateral with bilateral group (independent t-test).
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constriction, cecocentral scotoma, central scotoma,
arcuate scotoma, altitudinal visual field defect, blind
spot enlargement, temporal island, and nasal island.
We also found a visual field defect in five clinically
unaffected eyes in unilateral cases (21.7%).
VEP tests were performed in 24 cases, five bilateral
and 19 unilateral cases; all showed abnormality in-
cluding delay of latency and decreased amplitude in
affected eyes. Some patients only showed poor wave-
form or were barely recorded. Six unilateral cases
showed abnormality in clinically unaffected eyes (25%).
Twenty-three cases underwent radioimaging study
initially, including CT in 17 patients and MRI in six
patients. Ten (43.5%) patients showed optic nerve
thickening. Only one patient, who had been diag-
nosed with MS previously, showed marked atrophy of
the cerebral hemisphere on brain MRI. One case ini-
tially showed several white-matter plaques and MS
was diagnosed during follow-up. A total of four new
cases were diagnosed with MS in our neurology de-
partment during follow-up, among which one case
initially showed several white-matter plaques, one
case initially showed optic nerve swelling on MRI, one
case had a normal image on initial MRI, and one case
underwent no initial radioimaging. Two of the five MS
patients had bilateral ON and three had unilateral ON.
None had recurrence of ON. The vision of the two
bilateral recurrence cases were no light perception
(NLP) and counting fingers (CF), respectively, at the
last visit; the BCVA of unilateral recurrence cases were
6/6, 6/12, and CF, respectively, at the last visit.
Three cases were weakly positive for ANA and
three had elevated ESR. These six patients had no
obvious autoimmunologic disease on further immu-
nologic laboratory studies and consultation with an
immunologist during at least 1 year of follow-up.
Table 4. Improvement in color vision compared with initial visit
Unilateral p* Bilateral p**
2 weeks after treatment 12.23 ± 9.52 0.002 0.2 ± 0.45
1 month after treatment 13.45 ± 8.63 < 0.001 0.4 ± 0.55 0.374
3 months after treatment 13.09 ± 8.54 0.001 4.2 ± 8.84 0.374
6 months after treatment 13.73 ± 9.18 < 0.001 0.8 ± 1.30 0.374
1 year after treatment 13.45 ± 9.39 0.001 2.8 ± 5.72 0.374
























Figure. Visual acuity (VA; mean of logMAR) during follow-up.
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Diabetes mellitus was found in only one case. No
patients had a family history of ON or MS.
DISCUSSION
Patients aged 18–46 years who had suffered a first
attack of unilateral ON within the previous 8 days
were included in the ONTT study [3,9]. Patients with
visual symptom onset within 14 days were enrolled in
the present study, the same as the Japanese study [10].
Most ONTT patients were women (77.2%) with a me-
dian age of 31.8 years [9]. In the present study, 66.7%
of patients were female, with a mean age of 35.8 years
(range, 13–54 years). In Wakakura et al’s study, the
mean age was 36.3 years (range, 14–55 years) [10].
According to previous reports, about two-thirds of
ON patients have retrobulbar disease [2]. In the present
study, more than half of patients (55.6%) had retrobul-
bar disease, in both unilateral and bilateral groups.
Swollen discs were noted in 44.4% of our patients, 50%
in Wakakura et al’s study [10], and only 35% in the
ONTT [9]. Table 6 shows the comparison of the present
study with Wakakura et al’s studies and the ONTT;
the initial clinical features in our study were similar to
Wakakura et al’s findings [7,9,10]. Ocular or periocu-
lar pain was detected in 44.4% of our patients, whereas
it was observed in 56% of those in the Japanese studies,
and 92% in the ONTT. Only 7.4% of patients had
periventricular plaques and demyelination at the start
of the present study, in contrast to 14% in Wakakura et
al’s study and 48.7% in the ONTT.
The ONTT found that the classic ON visual field
pattern (central and cecocentral defects) was found in
only 8%, diffuse (nonfocal) depressions in 48%, and
arcuate, altitudinal, or nasal step defects in 20% [8,9].
ON does not appear to have a predilection for any
particular area of the visual field [11]. Diffuse visual
field defect was apparent in 37.5% of cases in Wakakura
et al’s study [10]. In the present study, we found a wide
variety of defect patterns. Eleven cases (47.8%) showed
diffuse depressions, while only five (21.7%) showed
central or cecocentral scotoma. Other visual field de-
fects included arcuate scotoma, temporal island, nasal
island, and blind spot enlargement (Table 5).
VEP abnormalities were often transitory, and many
normalized during follow-up. VEP is a sensitive tool
to reveal subclinical lesions. In the present study, six
cases showed VEP abnormality initially in the clini-
cally unaffected eye, two of which developed into ON
during the follow-up period. VEP abnormalities found
in clinically unaffected eyes predicted new onset of
ON in the ONTT [12].
In the ONTT, almost all patients with decreased
visual acuity also had abnormal color vision, and even
when visual acuity returned to 20/20 or better, color
tests were abnormal in 51.1% of patients [9]. In the
present study, only three unilateral cases (11.1%) showed
normal color vision (score 21) at the start of the
study. Nine cases (33.3%) showed normal color vision
at the final visit. These results seemed much worse
than those of the ONTT and Wakakura et al [7,13].
We compared the unilateral and bilateral groups.
The mean age was slightly greater in the unilateral
Table 5. Visual field abnormalities
Abnormality n (%)
Diffuse depression 11 (47.8%)
Central scotoma 4 (17.4%)
Altitudinal visual field defect 2 (8.7%)
Arcuate scotoma 2 (8.7%)
Blind spot enlargement 1 (4.3%)
Nasal island 1 (4.3%)
Temporal island 1 (4.3%)
Cecocentral scotoma/Others 1 (4.3%)
Table 6. Comparison of initial clinical features with those in other studies
Present study Japan [7,10] ONTT [9]
Ocular pain 44.4% 56% 92%
Periventricular plaques 7.4% 14% 49%
Swollen disc 44.4% 50% 35%
ON in definite multiple sclerosis 3.7% 5.6% 13%
ONTT = Optic Neuritis Treatment Trial; ON = optic neuritis.
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group than in the bilateral group (Table 2). There was
a higher proportion of females in the bilateral group
(80%) than in the unilateral group (63.7%). Disc edema
and ocular pain results were similar between the two
groups: more patients had retrobulbar disease and
fewer patients complained of periocular pain than in
the ONTT. Unilateral cases had better initial and final
visual function including visual acuity and color vision.
Visual acuity and color vision started to improve
within the first 2 weeks following treatment in the
unilateral group, and visual acuity was similar at 2
weeks and 1 year. Visual acuity in the bilateral group
did not significantly improve following treatment.
Visual function including visual acuity and color vi-
sion improved more quickly in the unilateral group
than in the bilateral group during the 1-year follow-
up. Patients with unilateral disease had better progno-
sis in visual function than those with bilateral disease
(Figure).
MRI was the best method to diagnose MS. The
detection rate of central nervous system plaques in
acute ON patients is high in Western countries, about
52–72% [14]. Lack of pain, the presence of optic disc
swelling, and mild visual acuity loss were features of
ON associated with a low risk of MS among patients
who had no brain MRI lesions and no history of neu-
rologic symptoms or ON in the other eye [1,15]. The 5-
year cumulative probability of clinically definite MS
was 30% in the ONTT. The risk of MS following ON is
highly dependent on the number of lesions present on
brain MRI [15]. Fewer patients in the present study
showed lesions compatible with MS on neuroimaging
study, and fewer patients developed MS during fol-
low-up than in the ONTT and Western countries.
Five cases (14.8%) had been diagnosed with MS in
our series by the last follow-up. The incidence of MS
after the onset of ON ranges from 45 to 85% according
to the follow-up period [16–19]. At the start of this
study, only one case (4.35%) had definite MS, in con-
trast to 13% of patients in the ONTT and 6% in the
Japanese study. In the present study, the association of
MS with ON was weaker than in the ONTT and other
studies in Western countries [16–20].
The prevalence of MS has been reported to be low
in Oriental populations. For example, in Japan, South
Korea, North Korea, and China, the prevalence is
apparently about 2–4 per 100,000. At comparable lati-
tudes in North America and Europe, inhabited largely
by Caucasians, the prevalence of MS is 10 to 30 times
higher [20]. One possible explanation for the difference
is that demyelinating disease in Orientals might be an
atypical or abortive form. A study of MS in Hawaiians
showed that a high proportion of Oriental cases had
ON as the presenting feature [20].
According to a clinical treatment trial in Japan,
methylprednisolone pulse treatment led to faster re-
covery of visual function than in the control group
(treated with mecobalamin), particularly visual acuity
at 1 week, visual field analyzer mean deviation at 3
weeks, and color vision at 1 week. Visual function test
results at 12 weeks and 1 year were essentially the
same in the two groups [7]. The ONTT found that
administration of high-dose intravenous methylpred-
nisolone followed by oral prednisolone (1 mg/dg/day)
for 11 days led to slightly faster recovery of visual
function than placebo, especially within the first 3
weeks following treatment. However, the final visual
acuity in these patients after 6 months was not signifi-
cantly different from that in the placebo group [3,21].
Treatment with oral prednisolone (1 mg/kg/day) alone
for 14 days has no beneficial effect on visual recovery
and increases the recurrence of ON [22,23]. A German
study to determine the effects of oral prednisolone
showed that the visual function of patients with ON
improved rapidly during the initial phase of treat-
ment [13]. In the present study, visual function in the
unilateral group, including visual acuity and color vision,
improved significantly within the first 2 weeks follow-
ing treatment. Visual acuity in unilateral cases at 2 weeks
and 1 year were not statistically different (Table 3).
The side effects of systemic corticosteroids should
always be considered, such as difficulty sleeping,
euphoria, dyspepsia, facial flushing, psychotic
depression, and even acute pancreatitis. Mild and
reversible complaints are more common than more
serious side effects [7,24]. Some of these complaints
were noted in the present study, including insomnia,
euphoria, facial flushing, and dyspepsia.
ON remains a disorder that is diagnosed on clinical
grounds. Pulse therapy followed by oral corticosteroids
is still recommended for de novo ON. The only factor
of value in predicting the visual outcome is initial
severity of vision loss. In most patients with ON,
visual recovery is rapid. Patients not following the
usual course of visual recovery should be considered
atypical [4].
In summary, the incidence of ocular pain in the
present study was lower than in the ONTT, the number
Optic neuritis
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of patients with optic disc swelling was higher, and
fewer patients had plaques on MRI. These initial clini-
cal features were closer to the findings of Wakakura et
al. These characteristic features may be related to the
low risk of MS in Chinese. Racial differences should be
considered when comparing the findings between the
present study and other studies. In addition, the fol-
low-up period was short and the number of cases was
small, so further evaluation is necessary. Finally, in
comparison with the bilateral group, the unilateral
group had better initial visual function, better
improvement, and better visual outcome during fol-
low-up.
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